Navigation Links
Niusule Announces Key Additions to Management Team
Date:11/13/2009

MONROVIA, Calif. and HANGZHOU, China, Nov. 13 /PRNewswire-FirstCall/ -- Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that Mr. Ping (Vince) Huang was named the Company's chief financial officer on November 6, 2009. Previously, Ms. Qinghua Hu, the Company's chief executive officer, also served as Niusule's CFO. The Company also retained Mr. Pei Pei as chief marketing officer of Niusule Bioengineering (Hangzhou) Co. Ltd. (Niusule Bioengineering), the Company's subsidiary in China.

Mr. Huang's work experience includes key positions in investment banking, consulting, and business development. He most recently served as an investment consultant for PIEPS, an affiliate of Gemstong Capital, where he initiated and managed qualitative and quantitative analysis for buyout execution. Mr. Huang also worked on the University of Alabama-Birmingham's life-science entrepreneurship program, where he was responsible for analysis and market research related to the commercialization of intellectual property. Prior to that, Mr. Huang was a business analyst for Beijing Kawin Biotech Co., Ltd., coordinating regulatory approvals for manufacturing and control processes. He holds a Bachelor of Engineering degree with a major in Biopharmaceuticals from China Pharmaceutical University and a Masters of Business Administration specializing in Finance from the UCLA Anderson School of Management. Mr. Huang has a Ph.D. in Pharmacology and Toxicology from the University of Alabama, Birmingham. He is fluent in English and Mandarin.

Mr. Pei has a strong marketing background in the Pharmaceutical and Bioengineering industry. Prior to joining Niusule, he served as Marketing Manager of Zhejiang at Shanghai Longbin Biotechnology Co., Ltd. He also worked as Manager of Zhejiang Branch, at Beijing Sinceretime Pharmaceutical Company and as Sales Director of Shanghai Asia Pioneer Pharmaceutical Co.,

Ltd. Mr. Pei has a college degree from China University of Geosciences.

"We would like to welcome Mr. Huang and Mr. Pei on board. We look forward to working with them and believe they will make meaningful contributions to Niusule. Mr. Huang's solid financial background will enhance our corporate finance, financial reporting and internal controls. I am also pleased that Mr. Pei with his extensive marketing experience will be leading our aggressive market expansion strategy and assisting Niusule to achieve its goals," commented Ms. Qinghua Hu, CEO of Niusule Biotech Corp. "I am delighted that with these additions, I can now focus my full attention on business strategy and planning our future growth and development," added Ms. Hu.

About Niusule Biotech Corp.

Niusule Biotech Corp. ("Niusule" or "the Company"), through its wholly owned subsidiary Niusule Bioengineering (Hangzhou) Co. Ltd., markets and distributes health food and related products manufactured in the US to Chinese consumers. The Company launched its Niusule Gummy Bears nutritional supplements for children in September 2009 and its PlantFusion protein powder in July 2009. Niusule currently has a retail distribution network comprised of 36 outlets at high-end supermarkets and shopping malls in Zhejiang province and is aggressively seeking to expand into other regions in China. Niusule was founded in April 2008 and is headquartered in Monrovia, California. For more information, contact CCG Investor Relations directly or go to Niusule's website at http://www.niusule.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained herein to reflect future events or developments. You are urged to consider these factors care in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

    Contact:

    Jeff Tsang
    Niusule Biotech Corp.
    (626) 446-4688
    Email: ir@niusule.com
    Website: www.niusule.com

    Mabel Zhang
    CCG Investor Relations
    (310) 954-1353
    mabel.zhang@ccgir.com
    www.ccgirasia.com

SOURCE Niusule Biotech Corp.


'/>"/>
SOURCE Niusule Biotech Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Announces Secondary Equity Offering
2. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
3. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
4. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
5. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
6. Milestone Scientific Announces Third Quarter 2009 Results
7. EF Johnson Technologies Announces Third Quarter Results
8. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
9. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
10. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
11. WIFH Atlanta Announces Breakthrough Technique in Laser Hair Removal for Ethnic Skin Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/10/2017)... Inc. (Nasdaq: HOLX ) announced today the ... April 1, 2017 .   GAAP diluted earnings per ... prior year period as the sale of the blood ... diluted EPS of $0.50 increased 6.4%.  Revenue of $715.4 ... Excluding the effects of blood screening and the acquired ...
Breaking Medicine Technology:
(Date:5/26/2017)... Boston, Massachsetts (PRWEB) , ... May 26, 2017 ... ... communities will gather at Boston CEO 2017 on May 30th and 31st at ... off-the-record networking forum for leading executives in the life sciences, offering exclusive access ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are ... menus. , “Boar’s Head fresh sliced meats and cheeses featured in these ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, a ... located on more than four acres of land at 5620 Sohl Avenue in Hammond, ... 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of the private apartments ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration Contractors ... its 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, ... , As part of BluSky’s partnership with The Adoption Exchange, BluSky will also ...
(Date:5/24/2017)... Ca (PRWEB) , ... May 24, 2017 , ... ... effects and background. Understanind and choosing the most appropriate instruments for research and ... critical in research finding. This webinar will focus on innovations in stereo microscopy ...
Breaking Medicine News(10 mins):